Latigo Biotherapeutics, Inc. (LTGO)

Price$23.04Cached quoteAs of 2026-09-05 14:33 UTC

AI: Fair-priced

Price checkThe valuation looks balanced because strong trial evidence offsets a large success premium.

With 66.3 million shares outstanding, the observed price implies about $1.47 billion of equity value. It is roughly 23% above the August offering price. Adding June cash of $55.0 million to $363.9 million of net offering proceeds gives about $419 million before later spending, leaving roughly $1.05 billion assigned to the drug pipeline. That is 3.5 times pro forma cash despite no product revenue and a $48.8 million first-half loss. The valuation requires substantial odds of late-stage success and commercial uptake.

Big pictureCash should fund major trials, but continued losses make approval and financing decisive.

Latigo has no approved product or current product revenue. During 2026's first half, it lost $48.8 million and used $48.4 million of operating cash, versus $46.8 million and $42.7 million one year earlier. Free cash flow—cash left after running and investing in the business—was about negative $48.5 million. The offering money is expected to fund operations into 2029, covering planned 2027 readouts, not commercialization. Pain demand is not strongly tied to economic cycles, but the stock remains tied to clinical events and financing markets.

Business strengthThe lead drug has encouraging pain data, yet one surgical setting is not enough.

In 343 abdominoplasty patients, high-dose onzotrigine reduced pain significantly versus placebo and produced a larger measured effect than the opioid comparator. Meaningful relief arrived in a median 52 minutes versus 83 minutes for the comparator; 52% avoided opioid rescue, versus 22% on placebo. The bear case is replication and safety: fever occurred in 7% versus 2% on placebo and near-fainting in 6% versus 1%. Vertex's approved same-class medicine validates the biological target but also creates direct competition.

What could change the storyLate-stage pain results could validate the premium, while failure would expose dilution risk.

The main test is whether the planned bunionectomy efficacy trial and broader safety trial reproduce acceptable pain relief and tolerability; both are due to report in the second half of 2027. The 120-patient knee osteoarthritis study could add a chronic-pain market at the same time. Conversely, failure, delay, or worse safety would leave no product revenue. The offering issued 22.08 million shares, nearly 10 million options were outstanding at June, and the equity plan can expand yearly, so eventual funding beyond the stated 2029 runway may dilute holders.

AI: News

Positive pain trialOnzotrigine cut postoperative pain and opioid rescue use, strengthening its path toward approval.

On July 29, the New England Journal of Medicine published the 343-patient study. High-dose onzotrigine's pain-score improvement versus placebo was 62.08 points, compared with 40.86 for hydrocodone-acetaminophen. Opioid rescue averaged 11.00 morphine-equivalent milligrams—a standard way to compare opioid doses—versus 18.35 with placebo, while 52% needed none versus 22%. Fever and near-fainting were more frequent than with placebo, so the late-stage program still must confirm safety and repeat the benefit.

Upsized public offeringHeavy demand expanded the offering and gave Latigo enough cash for planned trial readouts.

On August 6, Latigo priced 19.2 million shares, after which underwriters bought their full 2.88 million-share option. Total gross proceeds reached $397.4 million and net proceeds about $363.9 million. The shares opened about 17% above the offer but finished the first session only around 1% higher, showing enthusiasm alongside caution. Most importantly, the financing moved the expected cash runway into 2029 and reduced near-term funding risk before the 2027 trial results.

First quarterly updateThe first public update confirmed large cash losses but no slowdown in key programs.

On September 3, Latigo reported a $25.8 million second-quarter loss and $55.0 million of June cash before offering proceeds. It kept plans to start two late-stage onzotrigine trials in the second half of 2026 and target results in late 2027; the 120-patient LTG-321 knee study has the same readout window. Shares gained about 3% that day, but timing alone cannot establish that the update caused the move.

Loading local price history

Revenue

2024

2025

Net income

2024

2025

Free cash flow

2024

2025

Total cash / debt

CashTotal debt

2024

2025

2026

Financial statements

	2025	2024
Revenue	$4,000	$2.0M
Research & development	$3.0M	$1.3M
Operating expenses	$110.4M	$63.5M
Operating income	−$110.4M	−$63.5M
Operating margin	−2,759,800.00%	−3,194.91%
EBITDA	−$110.1M	−$63.2M
EBITDA margin	−2,753,575.00%	−3,182.63%
Net income	$2.0M	$31,000
Net profit margin	50,600.00%	1.56%
Basic EPSper basic share	-$2.48	-$1.39
Diluted EPSper diluted share	$2,024.00	$31.00